bioMerieux (FR:BIM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
bioMerieux, a global leader in in vitro diagnostics, has announced the CE-marking of their new VIDAS VITAMIN B12 TOTAL test, which measures vitamin B12 levels in human serum or plasma. This automated quantitative test, which is essential for diagnosing potential B12 deficiencies, will be available on all VIDAS immunoassay systems. The launch aims to enhance the comprehensive VIDAS test portfolio and is set to begin in select countries at the end of 2024, with a wider release in early 2025.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.